Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial ...
Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...
SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...
Cardiovascular disease may be one of medicine’s oldest battlegrounds, but some of its most important technologies are still ...
WASHINGTON, DC — New European registry data on transcatheter aortic-valve replacement (TAVR) in patients at lower surgical risk than those studied in the pivotal randomized trials offers the ...
CEO Bernard Zovighian highlighted a sharpened focus strategy aligned with anticipated regulatory approvals and expansion across key product lines, noting, "These areas represent large and growing ...
SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results